№ lp_1_17084
File format: docx
Character count: 9514
File size: 278 KB
This document is an audit report evaluating the compliance with laboratory diagnostic and monitoring guidelines for von Willebrand disease set by the British Society for Haematology.
Year:
(not specified)
Region / city:
(not specified)
Topic:
Haematology, von Willebrand disease
Document type:
Audit report
Organization / institution:
British Society for Haematology
Author:
(not specified)
Target audience:
Healthcare professionals in haematology
Period of validity:
(not specified)
Approval date:
(not specified)
Date of changes:
(not specified)
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / City:
United States
Theme:
Medical necessity letter
Document type:
Medical letter
Organization / Institution:
Takeda Pharmaceuticals U.S.A., Inc.
Author:
Takeda Pharmaceuticals U.S.A., Inc.
Target audience:
Physicians, insurance providers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Year:
2023
Region / City:
Colchester
Topic:
Haematology, Blood Transfusion, Phlebotomy
Document Type:
User Guide
Organization / Institution:
East Suffolk and North Essex NHS Foundation Trust
Author:
Kathryn Hurst
Target Audience:
Hospital and community users of laboratory services
Effective Period:
From 1st July 2019
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2022
Region / city:
Birmingham
Subject:
Paediatric Oncology and Haematology
Document type:
Capability Framework
Organization / institution:
Royal College of Nursing, Children’s Cancer and Leukaemia Group (CCLG)
Author:
Sally Spencer, Helen Woodman
Target audience:
Advanced Clinical Practitioners, Clinical Supervisors
Period of validity:
Until March 2023
Date of approval:
March 2022
Date of revisions:
Annually for first three years, then every three years
Year:
2023
Region / City:
East of England
Topic:
Transfusion management, Haematology
Document type:
Toolkit
Institution:
East of England Regional Transfusion Committee
Author:
Nicola Jones
Target audience:
Haematology Consultants, Transfusion Leads, Hospital Transfusion Committees
Action period:
Not specified
Approval date:
Not specified
Date of amendments:
Not specified
Year:
2020
Region / city:
United Kingdom
Subject:
Haematology, Transfusion Medicine
Document type:
Guideline
Organization:
British Society for Haematology
Author:
Simon J Stanworth, Kerry Dowling, Nikki Curry, Heidi Doughty, Beverley J Hunt, Laura Fraser, Shruthi Narayan, Juliet Smith, Ian Sullivan, Laura Green
Target audience:
Haematology and transfusion professionals, medical practitioners in the UK
Effective period:
From 2020 onwards
Approval date:
Not specified
Amendment date:
Not specified
Date:
17 July 2024
Time:
10.30–11.30
Document Type:
Draft Minutes
Group:
London & South East Haematology & Trauma Group
Chair:
Fatts Chowdhury
Organisations Represented:
NHSBT; St Mary’s Hospital; Coventry & Warwickshire Path Services; Imperial College Healthcare NHS Trust; King’s College Hospital; University Hospitals Sussex; St George’s Hospital; University Hospital Coventry; University Hospital Southampton; Lincoln County Hospital; Barts Health NHS Trust; University Hospitals Plymouth; James Cook University Hospital; John Radcliffe Hospital Oxford; Addenbrookes Cambridge; St James University Hospital
Agenda Items:
Welcome and Introductions; Previous Minutes; Updates – Major Trauma Centres and KSS; Review Stock Position
Key Topics:
Blood stock levels; O-negative shortage; Plasma group changes; Platelet usage policy; RBC, FFP, PLT and Cryo issuance and wastage; LIMS switchover; Synnovis cyber attack; Patient Blood Management; Media campaign for donor recruitment
Related Period:
Previous meeting held on 24 April 2024
Author:
Stephen Leather
Owner:
Richard Adams
Approved by:
Richard Adams, Stephen Leather, Mark Longman
Review Interval:
2 years or as required
Location of Hardcopies:
Cross site document-Electronic copy only(access via laboratory handbook website and Q pulse)
Changes from last version of this document:
Changed title of document to Haematology Reference Ranges, as it now also contains ESR reference ranges. Added normal range for immature granulocytes.
Background:
A reference range or reference interval is the range of values that is deemed normal for a physiological measurement in healthy persons. The standard definition of a reference range for a particular measurement is defined as the interval between which 95% of values of a reference population fall into, in such a way that 2.5% of the time a value will be less than the lower limit of this interval, and 2.5% of the time it will be larger than the upper limit of this interval, whatever the distribution of these values.
Normal ranges in adults:
Reference ranges have been verified based on the local population. A sample of over 500 normal results was gathered and a mean and standard deviation for each parameter was obtained. Any outliers (>3.0 SD) were removed, and an upper and lower limit were obtained by calculation of the 2.5 and 97.5 percentile. This data is stored on Q pulse HA-INF-REFHAEM DATA. For the reticulocyte normal range, results from over 3500 patients were gathered and a range established as detailed above. This data is stored on Q pulse HA-INF-REFRETIC DATA. Our reference ranges were compared against published literature providing ranges established by national and/or international consensus. In order to provide a harmonised normal range between York and Scarborough a lymphocyte range of 0.5-4.0 was selected. All requests sent to the lab with no age or sex, may be entered as unknown, and therefore will be allocated an adult female reference range. All reference ranges are to 1 decimal place. The pregnancy Haemoglobin (Hb) reference range was taken from the BCSH guidance and agreed by the Consultant for Obstetrician and Gynaecologist for all women marked as pregnant.
Normal ranges in infants and children:
Due to issues surrounding generation of internal ranges due to lack of available data; reference ranges for children are wholly derived from several published sources.
ESR reference ranges:
In healthy subjects, the erythrocyte sedimentation rate (ESR) is higher in women than in men, and in both sexes, a rise occurs with age.
References:
Practical Haematology, 11th edition 2012, Dacie & Lewis. Blood Cells-A Practical Guide, 4th edition, 2006, Barbara J Bain. Pediatric Haematology, 3rd edition 2006 Robert J. Arceci et al
Note:
Year
Recruitment reference number:
L8269
Position title:
Clinical Nurse Specialist (Haematology)
Institution:
Letterkenny University Hospital
Organisation:
Health Service Executive (HSE)
Document type:
Recruitment and selection information document
Purpose:
Information on recruitment and selection process
Application method:
Digital Application Form via Rezoomo
Contact email:
[email protected]
Eligibility criteria:
Detailed in Appendix 1
Applicant categories:
EEA, Swiss, British and Non-EEA applicants
Selection process elements:
Eligibility check, short-listing, interview, panel formation
Panel duration:
Lifetime of the panel as outlined in Job Specification
Equal opportunities statement:
HSE is an equal opportunities employer
Security clearance:
Required as part of recruitment process
Related appendices:
Eligibility Criteria; EEA / Swiss / British and Non-EEA Applicants; Clearances; Interview Reasonable Accommodation Process Flowchart
Topic:
General Physiology
Number of competencies:
09
Number of procedures that require certification:
NIL
Academic Phase:
Phase I
Target group:
Phase I students
Domain:
Knowledge (K)
Level:
KH
Core competencies:
Yes
Teaching learning methods:
Lecture, Small group discussion
Assessment methods:
Written examination, Viva voce
Vertical integration:
Pathology
Horizontal integration:
Biochemistry
Note:
Topic
Haematology
Year:
2023
Region / City:
Not specified
Topic:
Haematology, Self-Management Pathway
Document Type:
Guidelines
Organization / Institution:
National Comprehensive Cancer Network, BSH, UCLH, Southampton
Author:
Not specified
Target Audience:
Healthcare professionals
Effective Period:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Job Title:
Senior Biomedical Scientist (BMS) (Haematology Dept)
Band:
AFC Band 7
Responsible To:
Blood Science Deputy Laboratory Manager
Accountable To:
Blood Science Deputy Laboratory Manager
Section/Department/Directorate:
Haematology / Blood Science / Pathology, Clinical Support & Specialist Services
Location:
Pathology, NDDH
Working Hours:
37.5 hours per week plus night and weekend working
Service Provision:
24 hours per day, 7 days per week
Team Context:
Lead role within a team of 13 staff
Specimen Volume:
Approximately 1100 specimens daily
Specialist Areas:
Haematology, Blood Transfusion, Sickle Cell & Thalassaemia Screening, Haemoglobinopathies, Thrombophilia
Regulatory Compliance:
ISO 15189, UKAS, MHRA, BSQR, NICE guidelines
Laboratory Information System:
Epic/Beaker (Haematology module)
Reporting Structure:
Reports to Blood Sciences (Deputy) Manager
Key Relationships:
Medical staff, Nursing staff, Consultant staff, Clinical Service Managers, NHS Trust staff, General public, Trade representatives
Core Responsibilities:
Diagnostic analysis, quality control validation, staff supervision and training, specialist testing management, blood product provision, emergency response coordination
Committees Represented:
Pathology Health and Safety Committee, Pathology Training Committee, Pathology Quality Committee
Year:
2026
Region / City:
Australia
Theme:
Haematology Training
Document Type:
Application Form
Organization:
Royal College of Pathologists of Australasia (RCPA)
Author:
Royal College of Pathologists of Australasia
Target Audience:
Laboratories and Educational Institutions in Haematology
Validity Period:
Not specified
Approval Date:
Not specified
Date of Modifications:
Not specified
Year:
2023
Region / City:
Greater Glasgow & Clyde
Subject:
Healthcare management, Clinical Haematology
Document Type:
Job Description
Organization:
NHS Greater Glasgow & Clyde
Author:
Not specified
Target Audience:
Healthcare professionals, potential job candidates
Period of Validity:
Ongoing
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Region / City:
Letterkenny, Ireland
Sector:
Health / Haematology Nursing
Document Type:
Job Specification and Terms of Employment
Institution:
Letterkenny University Hospital, HSE West & North West Region
Position:
Clinical Nurse Specialist (Haematology)
Grade Code:
2697
Salary Range:
€61,463–€77,666
Application Method:
Rezoomo online submission
Closing Date:
12 February 2026, 16:00
Interview Notice:
Minimum two weeks
Appointment Type:
Permanent, 1 WTE
Services Covered:
Haematology inpatient and outpatient care, patient surveillance, multidisciplinary team involvement
Academic Partner:
University of Galway
Population Served:
830,000
Staffing:
Over 20,000 employees in region
Guiding Principles:
Care, Compassion, Trust, Learning
Mission and Values:
Patient-centered care, quality, integrity, team working, communication
Jahr:
2026
Organisation:
Align Technology, Inc.
Art des Dokuments:
Nutzungsbedingungen
Thema:
Webportal, Software, Dienstleistungen
Zielgruppe:
Nutzer des Webportals, Labore und medizinische Fachkräfte
Geltungsbereich:
Weltweit
Datum der Veröffentlichung:
2026
Lizenztyp:
Beschränkt, nicht übertragbar, nicht exklusiv
Datenverarbeitung:
Nutzung, Registrierung, Telemetrie
Year:
2025
Region / City:
United States
Theme:
Medical necessity letter
Document type:
Medical letter
Organization / Institution:
Takeda Pharmaceuticals U.S.A., Inc.
Author:
Takeda Pharmaceuticals U.S.A., Inc.
Target audience:
Physicians, insurance providers
Period of validity:
Not specified
Approval date:
Not specified
Date of changes:
Not specified
Jahr:
2021
Region / Land:
Australien
Thema:
Spinale Muskelatrophie, Gen-Therapie
Dokumenttyp:
Einreichungsunterlagen / klinische Zusammenfassung
Organisation / Institution:
Novartis Pharmaceuticals Australia Pty Ltd, Pharmaceutical Benefits Advisory Committee (PBAC)
Medikament:
Onasemnogene abeparvovec (Zolgensma®)
Zielpopulation:
Säuglinge <9 Monate mit bi-allelischen SMN1-Mutationen und 3 Kopien des SMN2-Gens
Behandlungsart:
Prä-symptomatische intravenöse Einzelinfusion
Regulierungsstatus:
Zugelassen durch TGA am 4. März 2021
Frühere PBAC-Empfehlung:
Prä-symptomatische Behandlung bei 1-2 Kopien des SMN2-Gens empfohlen (September 2021)
Wichtige Studien:
SPR1NT
Vergleichsgruppe:
Patienten mit 1-2 Kopien des SMN2-Gens behandelt mit ONA
Schlüsselparameter:
Entwicklungsmilestones, Sicherheit
Year:
2017
Region / City:
Winnipeg, Canada
Subject:
Pediatric Pain Relief, Research
Document Type:
Biography
Organization:
University of Saskatchewan, University of Manitoba
Author:
Carl L von Baeyer
Target Audience:
Medical professionals, researchers, healthcare providers
Period of Validity:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified